Clinical analysis of adverse reactions to second line anti TB drugs Source: Annual Congress 2012 - Tuberculosis: clinical findings I Year: 2012
Evaluation of drug induced liver injury due to anti tuberculous drugs in directly observed daily therapy Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Treatment outcome of multidrug resistant tuberculosis with second line drugs Source: Eur Respir J 2001; 18: Suppl. 33, 314s Year: 2001
Retrial of identical agents in patients with toxic hepatitis caused by first line antituberculosis drugs Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Protective effect of N-acetylcysteine on anti tuberculosis drug-induced hepatotoxicity Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009
A study of prescription of second line drugs in chronic tuberculosis patients before confirmation of multi drug resistance bacteriologically Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010
Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002
Individualized treatment regimens with second line anti-TB drugs (SLD) compared to first line anti-TB drug (FLD) only in new pulmonary TB patients, culture confirmed with full sensibility at drug sensibility test (DST) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Late Breaking Abstract - Preclinical study of anti-interleukin-4 alpha single domain antibody with therapeutic potential in asthma by oral inhalation Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions? Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016
Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003
Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 197s Year: 2007
Severe adverse effects of antitubercular drugs and patient management Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Airway administration of therapeutic antibody (tAb) confers higher protection than parenteral administration in a murine model of acute lung infection Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018
Adverse drug reactions to second line anti tuberculosis drugs: A prospective study in Mumbai, India Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Synergistic effects of anti-her-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines Source: Eur Respir J 2002; 20: Suppl. 38, 3s Year: 2002